EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease

Keith C Ferdinand, Fatima Rodriguez, Alok R Amraotkar, Subha Venkataraman, Imran Ayaz, Oliver Antequera, Hui Cao, Wenyue Zhu, Jing Wang, Michael D Shapiro

American Journal of Preventive Cardiology · 2026-06 · 27 · 101467

DOI: 10.1016/j.ajpc.2026.101467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-06. Verfasst von Keith C Ferdinand und 9 weiteren Autor:innen. Beteiligte Einrichtung: Tulane University School of Medicine, John W Deming Department of Medicine, Section of Cardiology, New Orleans, LA, USA. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novartis Pharma, Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Black and Hispanic individuals are disproportionately impacted by elevated levels of lipoprotein(a) [Lp(a)] and atherosclerotic cardiovascular disease (ASCVD). Despite this, these populations are underrepresented in cardiovascular clinical trials. Herein, the strategies aimed to improve minority representation during the study design and recruitment phase of the Lp(a)FRONTIERS EXPANSION trial are described. Baseline characteristics and study attrition to date are also presented.

Methods

Lp(a)FRONTIERS EXPANSION (NCT06267560) is a randomized, double-blind, phase 3b, placebo-controlled trial evaluating pelacarsen in United States (US) Black/African American and/or Hispanic individuals with elevated Lp(a) (≥125 nmol/L) and established ASCVD. Eligible individuals were randomized 2:1 to receive monthly subcutaneous injections of either pelacarsen 80 mg or placebo, for 12 months. Various design and operational strategies were employed to improve enrollment and retention under four key themes: study design, site selection and engagement, enrollment support, and barrier removal.

Results

Overall, 422 patients were randomized to receive pelacarsen or placebo, with enrollment completed 1 year ahead of schedule. Patients were randomized from 103 sites across 21 US states/territories (including Puerto Rico); 8 sites recruited ≥10 patients. At data cut-off (7 October 2025), 64 patients had completed the trial. The mean±standard deviation age was 63.2 ± 9.1 years, 50.7% (214/422) of patients were male, and 68.0% (287/422) identified as Black/African American. Median (Q1, Q3) Lp(a) levels were 110.3 (79.4, 143.7) mg/dL (226.6 [165.8, 299.7] nmol/L).

Conclusion

The Lp(a)FRONTIERS EXPANSION trial suggests that deliberate, culturally tailored design and operational strategies may improve cardiovascular trial participation by US minority populations. Results from Lp(a)FRONTIERS EXPANSION will provide critical insights into the efficacy and safety profile of pelacarsen in treating elevated Lp(a).

Schlagwörter

Stichwörter der Autor:innen

ASCVDLipoprotein(a)TQJ230Underrepresented diverse patientspelacarsen

Autor:innen und Institutionen

  • Tulane University School of Medicine, John W Deming Department of Medicine, Section of Cardiology, New Orleans, LA, USA.
  • Stanford University School of Medicine, Cardiovascular Medicine and the Center for Digital Health, Stanford, CA, USA.
  • Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
  • Novartis Pharmaceuticals UK Ltd, London, United Kingdom.
  • Wake Forest University School of Medicine, Center for Prevention of Cardiovascular Disease, Department of Cardiovascular Medicine, Winston-Salem, NC, USA.

Förderung

  • Novartis Pharma
  • Novartis Pharma AG

Zitieren

APA

Ferdinand, K. C., Rodriguez, F., Amraotkar, A. R., Venkataraman, S., Ayaz, I., Antequera, O., Cao, H., Zhu, W., Wang, J., & Shapiro, M. D. (2026). Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease. American Journal of Preventive Cardiology, 27, 101467. https://doi.org/10.1016/j.ajpc.2026.101467

Vancouver

Ferdinand KC, Rodriguez F, Amraotkar AR, Venkataraman S, Ayaz I, Antequera O, et al. Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease. American Journal of Preventive Cardiology. 2026;27:101467. doi:10.1016/j.ajpc.2026.101467

BibTeX
@article{Ferdinand2026,
  author = {Ferdinand, Keith C and Rodriguez, Fatima and Amraotkar, Alok R and Venkataraman, Subha and Ayaz, Imran and Antequera, Oliver and Cao, Hui and Zhu, Wenyue and Wang, Jing and Shapiro, Michael D},
  title = {Enhancing representation in cardiovascular trials: Lessons from Lp(a)FRONTIERS EXPANSION in United States Black and Hispanic patients with elevated lipoprotein(a) and established atherosclerotic cardiovascular disease},
  journal = {American Journal of Preventive Cardiology},
  year = {2026},
  volume = {27},
  pages = {101467},
  doi = {10.1016/j.ajpc.2026.101467}
}
Kostenlos starten →